{"id":"erdafitinib-monotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Stomatitis"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Retinal detachment or vision changes"}]},"_chembl":{"chemblId":"CHEMBL3545376","moleculeType":"Small molecule","molecularWeight":"446.56"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Erdafitinib is a pan-FGFR tyrosine kinase inhibitor that targets FGFR1, FGFR2, FGFR3, and FGFR4. By inhibiting FGFR signaling, it suppresses proliferation and survival of cancer cells that depend on aberrant FGFR activation, particularly those with FGFR alterations such as mutations or fusions. This mechanism is especially relevant in urothelial carcinoma and other cancers driven by FGFR dysregulation.","oneSentence":"Erdafitinib is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:59:44.716Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced or metastatic urothelial carcinoma with FGFR alterations"},{"name":"Other FGFR-driven solid tumors"}]},"trialDetails":[{"nctId":"NCT06511648","phase":"PHASE2","title":"Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations","status":"RECRUITING","sponsor":"Spanish Oncology Genito-Urinary Group","startDate":"2023-03-07","conditions":"Muscle-invasive Bladder Cancer","enrollment":90},{"nctId":"NCT03547037","phase":"PHASE1","title":"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2018-08-31","conditions":"Neoplasm","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Erdafitinib monotherapy","genericName":"Erdafitinib monotherapy","companyName":"Spanish Oncology Genito-Urinary Group","companyId":"spanish-oncology-genito-urinary-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Erdafitinib is a fibroblast growth factor receptor (FGFR) inhibitor that blocks FGFR signaling in cancer cells. Used for Locally advanced or metastatic urothelial carcinoma with FGFR alterations, Other FGFR-driven solid tumors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}